Menopause — MCQs

Q: Hormone replacement therapy can increase the risk of which of the following conditions?

Breast carcinoma. **Explanation:** The correct answer is **Breast carcinoma**. Hormone Replacement Therapy (HRT), specifically the combined estrogen-progestogen regimen, is associated with an increased risk of breast cancer. This risk is duration-dependent, typically becoming significant after 3–5 years of use. Estrogen promotes the proliferation of mammary epithelial cells, and the addition of progestogen further enhances this mitogenic effect, potentially promoting the growth of pre-existing occult tumors. **Analysis of Incorrect Options:** * **A. Osteoporosis:** HRT is actually **protective** against osteoporosis. Estrogen inhibits osteoclast activity and reduces bone resorption, thereby increasing bone mineral density and reducing the risk of fractures. * **C. Alzheimer’s Disease:** Current evidence suggests HRT does not increase the risk; some studies even suggest a "window of opportunity" where early initiation may be neuroprotective, though it is not indicated for dementia prevention. * **D. Colorectal Cancer:** Combined HRT has been shown to **decrease** the risk of colorectal cancer (by approximately 30% according to the Women's Health Initiative study). **High-Yield Clinical Pearls for NEET-PG:** * **WHI Study Findings:** HRT increases the risk of **Breast Cancer, Stroke, Venous Thromboembolism (VTE), and Coronary Heart Disease (CHD)**. * **Protective Effects:** HRT decreases the risk of **Osteoporotic fractures and Colorectal cancer**. * **Endometrial Cancer:** Unopposed estrogen increases the risk of endometrial cancer; therefore, progestogen must be added in women with an intact uterus. * **Indications:** The primary indication for HRT is the management of moderate-to-severe vasomotor symptoms (hot flashes) and urogenital atrophy.

Q: Estrogen replacement therapy is contraindicated in women with which of the following conditions?

Vasomotor symptoms. **Explanation:** The question asks for the condition where Estrogen Replacement Therapy (ERT) is **not** contraindicated. In medical terminology, if a drug is indicated for a condition, it is not contraindicated. **1. Why "Vasomotor Symptoms" is the correct answer:** Vasomotor symptoms (hot flashes, night sweats) are the **primary clinical indication** for Hormone Replacement Therapy (HRT/ERT). Estrogen effectively stabilizes the thermoregulatory center in the hypothalamus, which becomes dysfunctional due to estrogen deficiency during menopause. Therefore, it is the treatment of choice, not a contraindication. **2. Analysis of Incorrect Options (Absolute Contraindications):** * **Abnormal Genital Bleeding (Option A):** Undiagnosed vaginal bleeding is an absolute contraindication. It must be investigated first to rule out endometrial hyperplasia or malignancy, which estrogen could exacerbate. * **Known Case of Breast Cancer (Option B):** Estrogen is a potent mitogen for breast tissue. It is strictly contraindicated in women with a history of or active estrogen-dependent tumors (Breast or Endometrial cancer). * **Recent Thromboembolism (Option D):** Oral estrogen increases the synthesis of clotting factors in the liver and decreases antithrombin III. This pro-coagulant effect significantly increases the risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism. **3. NEET-PG High-Yield Pearls:** * **Absolute Contraindications for HRT:** Undiagnosed vaginal bleeding, pregnancy, active liver disease, history of VTE/DVT, and estrogen-dependent malignancies. * **Relative Contraindications:** Hypertension, migraine, gallbladder disease, and endometriosis. * **Clinical Tip:** For women with an intact uterus, estrogen must always be combined with **Progesterone** to prevent endometrial hyperplasia/cancer. ERT (estrogen alone) is only for women who have undergone a hysterectomy.

Q: A 47-year-old female presents with menopausal symptoms such as hot flashes and painful intercourse. Which of the following hormones would be expected to be elevated in this patient?

FSH. **Explanation:** The clinical presentation of hot flashes (vasomotor symptoms) and painful intercourse (atrophic vaginitis) in a 47-year-old woman is characteristic of the **perimenopausal transition**. **1. Why FSH is the Correct Answer:** The primary event in menopause is the depletion of the ovarian follicular pool. As the number of follicles decreases, there is a significant decline in the production of **Inhibin B** and **Estradiol**. Under normal physiological conditions, these hormones exert negative feedback on the anterior pituitary. With their decline, this negative feedback is lost, leading to a compensatory and marked **increase in Follicle-Stimulating Hormone (FSH)**. FSH is typically the first hormone to rise and is the most sensitive biochemical marker for ovarian failure. **2. Why the other options are incorrect:** * **Option B (Estrogen):** Estrogen levels (specifically Estradiol) **decrease** during menopause due to follicular exhaustion. Low estrogen is the direct cause of the patient’s symptoms (hot flashes and vaginal atrophy). * **Option C & D:** Since FSH rises and Estrogen falls, these options are physiologically incorrect. **Clinical Pearls for NEET-PG:** * **Diagnostic Threshold:** An FSH level **>40 mIU/mL** is generally considered diagnostic of menopause in the clinical context. * **Earliest Marker:** A rise in FSH is the earliest biochemical change, often occurring while LH levels are still normal. * **LH/FSH Ratio:** In menopause, the LH/FSH ratio reverses (FSH > LH). * **Post-menopausal Estrogen:** The predominant estrogen in post-menopausal women is **Estrone (E1)**, produced by the peripheral conversion of androstenedione in adipose tissue, rather than Estradiol (E2).

Q: What is the typical age range for the menopause transition in females?

40-51 years. **Explanation:** The **menopause transition (perimenopause)** is the physiological period preceding the final menstrual period (FMP), characterized by fluctuating hormone levels and irregular menstrual cycles. **1. Why Option C is Correct:** In most women, the transition begins in the early 40s and concludes with the menopause, for which the average age is **51 years** (range 45–55). The STRAW+10 (Stages of Reproductive Aging Workshop) criteria define the transition starting with increased cycle variability and ending 12 months after the FMP. Since the average onset is around age 45 and the average completion is 51, the range **40–51 years** best represents the typical clinical window for this transition. **2. Analysis of Incorrect Options:** * **Options A & B (30s):** Starting the transition in the early 30s is pathologically early. Menopause before age 40 is classified as **Premature Ovarian Insufficiency (POI)** and is not considered "typical." * **Option D (Up to 60 years):** While some women may experience late menopause, the vast majority complete the transition by age 52–55. A transition extending to age 60 is statistically rare and requires investigation for endometrial pathology. **High-Yield Clinical Pearls for NEET-PG:** * **Average age of Menopause:** 51 years (remains constant regardless of age at menarche or socioeconomic status). * **Earliest Hormonal Change:** A decrease in **Inhibin B**, leading to a compensatory (and diagnostic) **rise in FSH** (>40 IU/L). * **Most Common Symptom:** Vasomotor symptoms (hot flashes), caused by a narrowing of the thermoregulatory window in the hypothalamus. * **Smokers:** Experience menopause approximately **2 years earlier** than non-smokers due to the anti-estrogenic effects of nicotine.

Q: All except one are true about hormonal changes during menopause?

LH levels fall. In menopause, the primary physiological event is the **depletion of ovarian follicles**. This leads to a significant decrease in the production of Estrogen and Inhibin. ### Why Option B is the Correct Answer (False Statement) In a normal functioning hypothalamic-pituitary-ovarian (HPO) axis, Estrogen and Inhibin provide negative feedback to the pituitary gland. When these levels drop during menopause, the negative feedback is lost. Consequently, the pituitary gland increases the secretion of both **FSH and LH**. Therefore, **LH levels rise**, not fall. ### Explanation of Other Options * **A. FSH levels rise:** This is true. FSH rises more significantly than LH because Inhibin (which specifically suppresses FSH) is no longer produced by the follicles. An FSH level **>40 mIU/mL** is diagnostic of menopause. * **C. GnRH released at maximal frequency:** This is true. Due to the lack of negative feedback from estrogen, the hypothalamus pulses GnRH at its maximum frequency and amplitude to stimulate the pituitary. * **D. AMH levels fall:** This is true. Anti-Müllerian Hormone is produced by granulosa cells of pre-antral and small antral follicles. As the follicular pool depletes, AMH levels drop, often becoming undetectable years before the final menstrual period. ### NEET-PG High-Yield Pearls * **Earliest biochemical marker** of ovarian aging: **Decrease in Inhibin B**, followed by a rise in FSH. * **Most sensitive/reliable marker** for ovarian reserve: **AMH** (Anti-Müllerian Hormone). * **FSH/LH Ratio:** In menopause, FSH increases more than LH, resulting in an **FSH/LH ratio > 1**. * **Estrogen Source:** Post-menopause, the primary circulating estrogen is **Estrone (E1)**, produced by peripheral conversion of androstenedione in adipose tissue (compared to Estradiol/E2 in reproductive years).

Q: Estrogen replacement for postmenopausal symptoms causes an increase in:

Triglycerides. **Explanation:** The effect of Estrogen Replacement Therapy (ERT) on the lipid profile depends significantly on the route of administration. When estrogen is taken **orally**, it undergoes the "first-pass effect" in the liver. 1. **Why Triglycerides increase:** Oral estrogen stimulates the hepatic synthesis of triglycerides and increases the production of **VLDL (Very Low-Density Lipoprotein)** particles. Specifically, it enhances the expression of apolipoprotein C-III, which inhibits lipoprotein lipase, leading to an elevation in serum triglyceride levels. This is why oral ERT is often contraindicated in patients with severe hypertriglyceridemia (risk of pancreatitis). 2. **Why other options are incorrect:** * **LDL and Cholesterol:** Estrogen actually **decreases** LDL (the "bad" cholesterol) by increasing the expression of LDL receptors in the liver, leading to enhanced clearance. Consequently, total serum cholesterol levels typically decrease or remain stable. * **VLDL:** While VLDL production increases, the question specifically targets the primary lipid component measured in a standard profile that rises significantly—**Triglycerides**. In many clinical contexts, the rise in Triglycerides is the most clinically relevant adverse lipid change of oral ERT. **High-Yield Clinical Pearls for NEET-PG:** * **HDL:** Oral estrogen **increases HDL** (the "good" cholesterol), which is considered a cardioprotective effect. * **Route Matters:** **Transdermal estrogen** bypasses the liver, thus it has a neutral effect on triglycerides and is preferred in women with hypertriglyceridemia. * **Coagulation:** Oral estrogen increases clotting factors (II, VII, IX, X) and decreases Antithrombin III, increasing the risk of Venous Thromboembolism (VTE).

Q: What is the most common cause of postmenopausal vaginal bleeding?

Endometrial carcinoma. **Explanation:** Postmenopausal bleeding (PMB) is defined as vaginal bleeding occurring at least 12 months after the cessation of menstruation. In the context of the options provided, **Endometrial Carcinoma** is the most significant and common malignant cause of PMB. **1. Why Endometrial Carcinoma is the correct answer:** While **atrophic vaginitis/endometritis** is statistically the most common *benign* cause of PMB (occurring in ~60-80% of cases), among the choices listed, **Endometrial Carcinoma** is the most common *malignant* cause and the primary diagnosis a clinician must rule out. Approximately 10% of women with PMB will be diagnosed with endometrial cancer. It typically presents as painless, bright red or brown spotting. **2. Why the other options are incorrect:** * **Carcinoma of the cervix:** While it can cause postmenopausal bleeding, it more classically presents as post-coital bleeding or foul-smelling discharge. It is less common than endometrial cancer in the postmenopausal age group in developed settings, though it remains a significant differential in India. * **Carcinoma of the vulva:** This usually presents with a visible vulvar lump, pruritus, or chronic ulceration. Bleeding is a late and less common primary symptom. * **Ovarian tumor:** Most ovarian tumors are "silent." Estrogen-secreting tumors (like Granulosa cell tumors) can cause endometrial hyperplasia leading to bleeding, but the primary site of bleeding is still the endometrium, not the ovary itself. **Clinical Pearls for NEET-PG:** * **Gold Standard Investigation for PMB:** Transvaginal Ultrasound (TVS). * **Cut-off for Endometrial Thickness (ET):** If ET is **≤ 4 mm**, the risk of malignancy is 4 mm**, an endometrial biopsy (Pipelle or D&C) is mandatory. * **Most common benign cause of PMB:** Atrophic vaginitis. * **Most common malignant cause of PMB:** Endometrial carcinoma.

Q: Which of the following statements regarding hormone replacement therapy (HRT) is FALSE?

Decreases the risk for major coronary heart disease. **Explanation:** The correct answer is **D**. According to the landmark **Women’s Health Initiative (WHI) study**, combined HRT (Estrogen + Progestogen) does **not** provide cardioprotection and may actually **increase the risk of major coronary heart disease (CHD)** and stroke, especially when started in older postmenopausal women. While the "timing hypothesis" suggests a potential benefit if started early (within 10 years of menopause), for the purpose of standard guidelines and exams, HRT is not indicated for the prevention of cardiovascular disease. **Analysis of other options:** * **Option A (True):** Unopposed estrogen therapy leads to endometrial hyperplasia and significantly increases the risk of **endometrial cancer**. This is why progestogens are always added for women with an intact uterus. * **Option B (True):** Estrogen has neuroprotective properties. In healthy, symptomatic women during the early menopausal transition, HRT can improve cognitive functions like verbal memory and attention. * **Option C (True):** Paradoxically, the WHI Memory Study (WHIMS) showed that initiating HRT in women **aged 65 or older** may double the risk of developing dementia, including Alzheimer’s disease. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Most effective treatment for moderate-to-severe vasomotor symptoms (hot flashes) and genitourinary syndrome of menopause. * **Fracture Risk:** HRT **decreases** the risk of osteoporotic fractures (hip and spine). * **Cancer Risks:** Increases risk of **Breast Cancer** (with combined HRT >5 years) and **Gallbladder disease**. It **decreases** the risk of **Colorectal Cancer**. * **Contraindications:** Undiagnosed vaginal bleeding, history of DVT/PE, active liver disease, and estrogen-dependent tumors (Breast/Endometrial CA).

Q: Which of the following is a cause of menopause?

Primary ovarian failure. **Explanation:** **1. Why Primary Ovarian Failure is Correct:** Menopause is defined as the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is fundamentally a **primary ovarian failure**. As a woman ages, the pool of primordial follicles in the ovary becomes exhausted. These follicles become unresponsive to gonadotropins (FSH and LH). Consequently, estrogen and inhibin levels fall, leading to a loss of negative feedback on the pituitary. This results in the hallmark biochemical finding of menopause: **elevated gonadotropins (Hypergonadotropic Hypogonadism)**, specifically an FSH > 40 IU/L. **2. Why Other Options are Incorrect:** * **Options A & B:** Menopause is not caused by a lack of stimulation from the higher centers. In fact, the hypothalamus and pituitary remain functional and increase their secretions (GnRH and Gonadotropins) in a futile attempt to stimulate the failing ovaries. * **Option C:** While the HPO axis is indeed altered, "deranged functioning" is a vague clinical term. The specific underlying cause is the depletion of the ovarian follicle pool, not a primary defect in the regulatory axis itself. **3. High-Yield Clinical Pearls for NEET-PG:** * **Earliest Biochemical Marker:** A decrease in **Inhibin B** is the earliest sign of a declining ovarian reserve. * **Diagnostic Marker:** **FSH > 40 IU/L** is the gold standard for confirming menopause. * **Estrogen Shift:** Post-menopause, the predominant circulating estrogen changes from **Estradiol (E2)** to **Estrone (E1)**, which is produced by the peripheral conversion of androstenedione in adipose tissue. * **Average Age:** In India, the average age of menopause is approximately **46–48 years** (slightly earlier than the global average of 51).

Menopause Indian Medical PG Practice Questions and MCQs

Question 1: Hormone replacement therapy can increase the risk of which of the following conditions?

A. Osteoporosis
B. Breast carcinoma (Correct Answer)
C. Alzheimer's disease
D. Colorectal cancer

Explanation: **Explanation:** The correct answer is **Breast carcinoma**. Hormone Replacement Therapy (HRT), specifically the combined estrogen-progestogen regimen, is associated with an increased risk of breast cancer. This risk is duration-dependent, typically becoming significant after 3–5 years of use. Estrogen promotes the proliferation of mammary epithelial cells, and the addition of progestogen further enhances this mitogenic effect, potentially promoting the growth of pre-existing occult tumors. **Analysis of Incorrect Options:** * **A. Osteoporosis:** HRT is actually **protective** against osteoporosis. Estrogen inhibits osteoclast activity and reduces bone resorption, thereby increasing bone mineral density and reducing the risk of fractures. * **C. Alzheimer’s Disease:** Current evidence suggests HRT does not increase the risk; some studies even suggest a "window of opportunity" where early initiation may be neuroprotective, though it is not indicated for dementia prevention. * **D. Colorectal Cancer:** Combined HRT has been shown to **decrease** the risk of colorectal cancer (by approximately 30% according to the Women's Health Initiative study). **High-Yield Clinical Pearls for NEET-PG:** * **WHI Study Findings:** HRT increases the risk of **Breast Cancer, Stroke, Venous Thromboembolism (VTE), and Coronary Heart Disease (CHD)**. * **Protective Effects:** HRT decreases the risk of **Osteoporotic fractures and Colorectal cancer**. * **Endometrial Cancer:** Unopposed estrogen increases the risk of endometrial cancer; therefore, progestogen must be added in women with an intact uterus. * **Indications:** The primary indication for HRT is the management of moderate-to-severe vasomotor symptoms (hot flashes) and urogenital atrophy.

Question 2: Estrogen replacement therapy is contraindicated in women with which of the following conditions?

A. Abnormal genital bleeding
B. Known case of breast cancer
C. Vasomotor symptoms (Correct Answer)
D. Recent thromboembolism

Explanation: **Explanation:** The question asks for the condition where Estrogen Replacement Therapy (ERT) is **not** contraindicated. In medical terminology, if a drug is indicated for a condition, it is not contraindicated. **1. Why "Vasomotor Symptoms" is the correct answer:** Vasomotor symptoms (hot flashes, night sweats) are the **primary clinical indication** for Hormone Replacement Therapy (HRT/ERT). Estrogen effectively stabilizes the thermoregulatory center in the hypothalamus, which becomes dysfunctional due to estrogen deficiency during menopause. Therefore, it is the treatment of choice, not a contraindication. **2. Analysis of Incorrect Options (Absolute Contraindications):** * **Abnormal Genital Bleeding (Option A):** Undiagnosed vaginal bleeding is an absolute contraindication. It must be investigated first to rule out endometrial hyperplasia or malignancy, which estrogen could exacerbate. * **Known Case of Breast Cancer (Option B):** Estrogen is a potent mitogen for breast tissue. It is strictly contraindicated in women with a history of or active estrogen-dependent tumors (Breast or Endometrial cancer). * **Recent Thromboembolism (Option D):** Oral estrogen increases the synthesis of clotting factors in the liver and decreases antithrombin III. This pro-coagulant effect significantly increases the risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism. **3. NEET-PG High-Yield Pearls:** * **Absolute Contraindications for HRT:** Undiagnosed vaginal bleeding, pregnancy, active liver disease, history of VTE/DVT, and estrogen-dependent malignancies. * **Relative Contraindications:** Hypertension, migraine, gallbladder disease, and endometriosis. * **Clinical Tip:** For women with an intact uterus, estrogen must always be combined with **Progesterone** to prevent endometrial hyperplasia/cancer. ERT (estrogen alone) is only for women who have undergone a hysterectomy.

Question 3: A 47-year-old female presents with menopausal symptoms such as hot flashes and painful intercourse. Which of the following hormones would be expected to be elevated in this patient?

A. FSH (Correct Answer)
B. Estrogen
C. Both FSH and Estrogen
D. Neither FSH nor Estrogen

Explanation: **Explanation:** The clinical presentation of hot flashes (vasomotor symptoms) and painful intercourse (atrophic vaginitis) in a 47-year-old woman is characteristic of the **perimenopausal transition**. **1. Why FSH is the Correct Answer:** The primary event in menopause is the depletion of the ovarian follicular pool. As the number of follicles decreases, there is a significant decline in the production of **Inhibin B** and **Estradiol**. Under normal physiological conditions, these hormones exert negative feedback on the anterior pituitary. With their decline, this negative feedback is lost, leading to a compensatory and marked **increase in Follicle-Stimulating Hormone (FSH)**. FSH is typically the first hormone to rise and is the most sensitive biochemical marker for ovarian failure. **2. Why the other options are incorrect:** * **Option B (Estrogen):** Estrogen levels (specifically Estradiol) **decrease** during menopause due to follicular exhaustion. Low estrogen is the direct cause of the patient’s symptoms (hot flashes and vaginal atrophy). * **Option C & D:** Since FSH rises and Estrogen falls, these options are physiologically incorrect. **Clinical Pearls for NEET-PG:** * **Diagnostic Threshold:** An FSH level **>40 mIU/mL** is generally considered diagnostic of menopause in the clinical context. * **Earliest Marker:** A rise in FSH is the earliest biochemical change, often occurring while LH levels are still normal. * **LH/FSH Ratio:** In menopause, the LH/FSH ratio reverses (FSH > LH). * **Post-menopausal Estrogen:** The predominant estrogen in post-menopausal women is **Estrone (E1)**, produced by the peripheral conversion of androstenedione in adipose tissue, rather than Estradiol (E2).

Question 4: What is the typical age range for the menopause transition in females?

A. 30-49 years
B. 35-49 years
C. 40-51 years (Correct Answer)
D. 40-60 years

Explanation: **Explanation:** The **menopause transition (perimenopause)** is the physiological period preceding the final menstrual period (FMP), characterized by fluctuating hormone levels and irregular menstrual cycles. **1. Why Option C is Correct:** In most women, the transition begins in the early 40s and concludes with the menopause, for which the average age is **51 years** (range 45–55). The STRAW+10 (Stages of Reproductive Aging Workshop) criteria define the transition starting with increased cycle variability and ending 12 months after the FMP. Since the average onset is around age 45 and the average completion is 51, the range **40–51 years** best represents the typical clinical window for this transition. **2. Analysis of Incorrect Options:** * **Options A & B (30s):** Starting the transition in the early 30s is pathologically early. Menopause before age 40 is classified as **Premature Ovarian Insufficiency (POI)** and is not considered "typical." * **Option D (Up to 60 years):** While some women may experience late menopause, the vast majority complete the transition by age 52–55. A transition extending to age 60 is statistically rare and requires investigation for endometrial pathology. **High-Yield Clinical Pearls for NEET-PG:** * **Average age of Menopause:** 51 years (remains constant regardless of age at menarche or socioeconomic status). * **Earliest Hormonal Change:** A decrease in **Inhibin B**, leading to a compensatory (and diagnostic) **rise in FSH** (>40 IU/L). * **Most Common Symptom:** Vasomotor symptoms (hot flashes), caused by a narrowing of the thermoregulatory window in the hypothalamus. * **Smokers:** Experience menopause approximately **2 years earlier** than non-smokers due to the anti-estrogenic effects of nicotine.

Question 5: What is the characteristic finding in a postmenopausal ovary?

A. Preponderance of primordial follicles
B. Persistent corpora albicans (Correct Answer)
C. Decreased atretic follicles
D. Decreased corpora albicans

Explanation: **Explanation:** The transition to menopause is characterized by the exhaustion of the ovarian follicular pool. Once menopause is established, the ovaries undergo significant structural and functional changes. **Why "Persistent Corpora Albicans" is correct:** During the reproductive years, the corpus luteum (formed after ovulation) degenerates into a **corpus albicans** (a fibrous scar) if pregnancy does not occur. In the postmenopausal ovary, the lack of new follicular development means no new corpora lutea are formed. However, the existing corpora albicans are composed of dense collagenous tissue that is resistant to rapid resorption. Consequently, these "scars" persist within the shrunken, fibrotic ovarian stroma for many years, making them a characteristic histological finding. **Analysis of Incorrect Options:** * **A & C (Primordial and Atretic Follicles):** Menopause is defined by the near-total depletion of primordial follicles. While atresia is the process that leads to this depletion, the postmenopausal ovary is characterized by an **absence** of developing or atretic follicles, not a decrease in atretic follicles relative to active ones. * **D (Decreased Corpora Albicans):** This is incorrect because, as noted above, these structures do not disappear immediately; they accumulate and persist as the ovary undergoes senile atrophy. **High-Yield NEET-PG Pearls:** * **Ovarian Size:** Postmenopausal ovaries shrink significantly (atrophy) and typically measure less than 2 x 1.5 x 0.5 cm. * **Hormonal Profile:** The hallmark is **elevated FSH (>40 IU/L)** due to the loss of negative feedback from estrogen and Inhibin B. * **Stromal Activity:** Despite the loss of follicles, the ovarian stroma may remain active, secreting small amounts of **androstenedione and testosterone** under the influence of high LH levels. * **Palpable Ovary:** In a postmenopausal woman, a palpable ovary on physical exam is abnormal and warrants investigation to rule out malignancy (the "Postmenopausal Palpable Ovary Syndrome").

Question 6: All except one are true about hormonal changes during menopause?

A. FSH levels rise
B. LH levels fall (Correct Answer)
C. GnRH released at maximal frequency
D. AMH levels fall

Explanation: In menopause, the primary physiological event is the **depletion of ovarian follicles**. This leads to a significant decrease in the production of Estrogen and Inhibin. ### Why Option B is the Correct Answer (False Statement) In a normal functioning hypothalamic-pituitary-ovarian (HPO) axis, Estrogen and Inhibin provide negative feedback to the pituitary gland. When these levels drop during menopause, the negative feedback is lost. Consequently, the pituitary gland increases the secretion of both **FSH and LH**. Therefore, **LH levels rise**, not fall. ### Explanation of Other Options * **A. FSH levels rise:** This is true. FSH rises more significantly than LH because Inhibin (which specifically suppresses FSH) is no longer produced by the follicles. An FSH level **>40 mIU/mL** is diagnostic of menopause. * **C. GnRH released at maximal frequency:** This is true. Due to the lack of negative feedback from estrogen, the hypothalamus pulses GnRH at its maximum frequency and amplitude to stimulate the pituitary. * **D. AMH levels fall:** This is true. Anti-Müllerian Hormone is produced by granulosa cells of pre-antral and small antral follicles. As the follicular pool depletes, AMH levels drop, often becoming undetectable years before the final menstrual period. ### NEET-PG High-Yield Pearls * **Earliest biochemical marker** of ovarian aging: **Decrease in Inhibin B**, followed by a rise in FSH. * **Most sensitive/reliable marker** for ovarian reserve: **AMH** (Anti-Müllerian Hormone). * **FSH/LH Ratio:** In menopause, FSH increases more than LH, resulting in an **FSH/LH ratio > 1**. * **Estrogen Source:** Post-menopause, the primary circulating estrogen is **Estrone (E1)**, produced by peripheral conversion of androstenedione in adipose tissue (compared to Estradiol/E2 in reproductive years).

Question 7: Estrogen replacement for postmenopausal symptoms causes an increase in:

A. LDL
B. Cholesterol
C. VLDL
D. Triglycerides (Correct Answer)

Explanation: **Explanation:** The effect of Estrogen Replacement Therapy (ERT) on the lipid profile depends significantly on the route of administration. When estrogen is taken **orally**, it undergoes the "first-pass effect" in the liver. 1. **Why Triglycerides increase:** Oral estrogen stimulates the hepatic synthesis of triglycerides and increases the production of **VLDL (Very Low-Density Lipoprotein)** particles. Specifically, it enhances the expression of apolipoprotein C-III, which inhibits lipoprotein lipase, leading to an elevation in serum triglyceride levels. This is why oral ERT is often contraindicated in patients with severe hypertriglyceridemia (risk of pancreatitis). 2. **Why other options are incorrect:** * **LDL and Cholesterol:** Estrogen actually **decreases** LDL (the "bad" cholesterol) by increasing the expression of LDL receptors in the liver, leading to enhanced clearance. Consequently, total serum cholesterol levels typically decrease or remain stable. * **VLDL:** While VLDL production increases, the question specifically targets the primary lipid component measured in a standard profile that rises significantly—**Triglycerides**. In many clinical contexts, the rise in Triglycerides is the most clinically relevant adverse lipid change of oral ERT. **High-Yield Clinical Pearls for NEET-PG:** * **HDL:** Oral estrogen **increases HDL** (the "good" cholesterol), which is considered a cardioprotective effect. * **Route Matters:** **Transdermal estrogen** bypasses the liver, thus it has a neutral effect on triglycerides and is preferred in women with hypertriglyceridemia. * **Coagulation:** Oral estrogen increases clotting factors (II, VII, IX, X) and decreases Antithrombin III, increasing the risk of Venous Thromboembolism (VTE).

Question 8: What is the most common cause of postmenopausal vaginal bleeding?

A. Endometrial carcinoma (Correct Answer)
B. Carcinoma of the cervix
C. Carcinoma of the vulva
D. Ovarian tumor

Explanation: **Explanation:** Postmenopausal bleeding (PMB) is defined as vaginal bleeding occurring at least 12 months after the cessation of menstruation. In the context of the options provided, **Endometrial Carcinoma** is the most significant and common malignant cause of PMB. **1. Why Endometrial Carcinoma is the correct answer:** While **atrophic vaginitis/endometritis** is statistically the most common *benign* cause of PMB (occurring in ~60-80% of cases), among the choices listed, **Endometrial Carcinoma** is the most common *malignant* cause and the primary diagnosis a clinician must rule out. Approximately 10% of women with PMB will be diagnosed with endometrial cancer. It typically presents as painless, bright red or brown spotting. **2. Why the other options are incorrect:** * **Carcinoma of the cervix:** While it can cause postmenopausal bleeding, it more classically presents as post-coital bleeding or foul-smelling discharge. It is less common than endometrial cancer in the postmenopausal age group in developed settings, though it remains a significant differential in India. * **Carcinoma of the vulva:** This usually presents with a visible vulvar lump, pruritus, or chronic ulceration. Bleeding is a late and less common primary symptom. * **Ovarian tumor:** Most ovarian tumors are "silent." Estrogen-secreting tumors (like Granulosa cell tumors) can cause endometrial hyperplasia leading to bleeding, but the primary site of bleeding is still the endometrium, not the ovary itself. **Clinical Pearls for NEET-PG:** * **Gold Standard Investigation for PMB:** Transvaginal Ultrasound (TVS). * **Cut-off for Endometrial Thickness (ET):** If ET is **≤ 4 mm**, the risk of malignancy is <1%. If ET is **> 4 mm**, an endometrial biopsy (Pipelle or D&C) is mandatory. * **Most common benign cause of PMB:** Atrophic vaginitis. * **Most common malignant cause of PMB:** Endometrial carcinoma.

Question 9: Which of the following statements regarding hormone replacement therapy (HRT) is FALSE?

A. Increases the risk for endometrial cancer
B. Improves cognitive performance in healthy women
C. May increase the risk of Alzheimer's disease
D. Decreases the risk for major coronary heart disease (Correct Answer)

Explanation: **Explanation:** The correct answer is **D**. According to the landmark **Women’s Health Initiative (WHI) study**, combined HRT (Estrogen + Progestogen) does **not** provide cardioprotection and may actually **increase the risk of major coronary heart disease (CHD)** and stroke, especially when started in older postmenopausal women. While the "timing hypothesis" suggests a potential benefit if started early (within 10 years of menopause), for the purpose of standard guidelines and exams, HRT is not indicated for the prevention of cardiovascular disease. **Analysis of other options:** * **Option A (True):** Unopposed estrogen therapy leads to endometrial hyperplasia and significantly increases the risk of **endometrial cancer**. This is why progestogens are always added for women with an intact uterus. * **Option B (True):** Estrogen has neuroprotective properties. In healthy, symptomatic women during the early menopausal transition, HRT can improve cognitive functions like verbal memory and attention. * **Option C (True):** Paradoxically, the WHI Memory Study (WHIMS) showed that initiating HRT in women **aged 65 or older** may double the risk of developing dementia, including Alzheimer’s disease. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Most effective treatment for moderate-to-severe vasomotor symptoms (hot flashes) and genitourinary syndrome of menopause. * **Fracture Risk:** HRT **decreases** the risk of osteoporotic fractures (hip and spine). * **Cancer Risks:** Increases risk of **Breast Cancer** (with combined HRT >5 years) and **Gallbladder disease**. It **decreases** the risk of **Colorectal Cancer**. * **Contraindications:** Undiagnosed vaginal bleeding, history of DVT/PE, active liver disease, and estrogen-dependent tumors (Breast/Endometrial CA).

Question 10: Which of the following is a cause of menopause?

A. Ovarian failure secondary to cessation of pituitary secretion of gonadotropins
B. Ovarian failure secondary to cessation of hypothalamic secretion of GnRH
C. Deranged hypothalamic-pituitary-ovarian axis functioning
D. Primary ovarian failure (Correct Answer)

Explanation: **Explanation:** **1. Why Primary Ovarian Failure is Correct:** Menopause is defined as the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is fundamentally a **primary ovarian failure**. As a woman ages, the pool of primordial follicles in the ovary becomes exhausted. These follicles become unresponsive to gonadotropins (FSH and LH). Consequently, estrogen and inhibin levels fall, leading to a loss of negative feedback on the pituitary. This results in the hallmark biochemical finding of menopause: **elevated gonadotropins (Hypergonadotropic Hypogonadism)**, specifically an FSH > 40 IU/L. **2. Why Other Options are Incorrect:** * **Options A & B:** Menopause is not caused by a lack of stimulation from the higher centers. In fact, the hypothalamus and pituitary remain functional and increase their secretions (GnRH and Gonadotropins) in a futile attempt to stimulate the failing ovaries. * **Option C:** While the HPO axis is indeed altered, "deranged functioning" is a vague clinical term. The specific underlying cause is the depletion of the ovarian follicle pool, not a primary defect in the regulatory axis itself. **3. High-Yield Clinical Pearls for NEET-PG:** * **Earliest Biochemical Marker:** A decrease in **Inhibin B** is the earliest sign of a declining ovarian reserve. * **Diagnostic Marker:** **FSH > 40 IU/L** is the gold standard for confirming menopause. * **Estrogen Shift:** Post-menopause, the predominant circulating estrogen changes from **Estradiol (E2)** to **Estrone (E1)**, which is produced by the peripheral conversion of androstenedione in adipose tissue. * **Average Age:** In India, the average age of menopause is approximately **46–48 years** (slightly earlier than the global average of 51).

Practice by Chapter

Physiology of Menopause

Practice Questions

Perimenopausal Transition

Practice Questions

Menopausal Symptoms and Management

Practice Questions

Hormone Replacement Therapy

Practice Questions

Non-hormonal Management Options

Practice Questions

Osteoporosis Prevention and Management

Practice Questions

Cardiovascular Health in Menopause

Practice Questions

Urogenital Atrophy

Practice Questions

Psychological Aspects of Menopause

Practice Questions

Premature Menopause

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?